Barilla Opens Its New Innovation Center to Drive Food Innovation Worldwide
18.11.2025 12:37:00 CET | Business Wire | Press release
A reimagined space where research, technology, and collaboration merge with global expertise to advance the future of Barilla’s pasta, sauces, and bakery products
How can we bring the excellence of Italian culinary tradition into the future? How can we transform everyday products into experiences that surprise the senses, create emotions, and accompany people in moments of pleasure, sharing, and discovery? The answer for Barilla Group is the Barilla Innovation & Technology Experience (BITE) in Parma, marking the company’s most significant investment in food innovation in recent years. With almost 14,000m², more than €20 million invested and an additional €2 million per year dedicated to equipment upgrades, BITE stands as a global hub designed to foster development across the Group’s portfolio. Pasta, sauces, and bakery become a territory of exploration here, where research and technology serve Barilla's passion for good food.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251118376430/en/

Guido, Paolo and Luca Barilla. © Barilla
Rooted in an approach of collaboration with leading international minds, this new Innovation Center brings together a team of 200highly skilled experts, including food technologists, researchers, engineers, designers, professional tasters and chefs, to develop the next generation of Barilla high-quality food products. Each year, 30 young talents from both Italy and abroad join Barilla’s RDQ community through dedicated internship or other post-graduate programs, with interns coming from countries such as Turkey, Belgium, Greece, and Spain over the past two years. The center is also the beating heart of an open innovation ecosystem that already has 84 active collaborations with universities and research centers in Italy and around the world.
“At Barilla, where the product has always been at the heart of everything we do, we know that a fundamental part of our work is to imagine and create quality products that must respond and adapt to people’s evolving needs,” says Guido Barilla, Chairman of the Barilla Group. “The BITE, in addition to shaping what will be the products of tomorrow, represents a very clear entrepreneurial choice. Barilla must drive and anticipate trends and be able to engage with markets that are increasingly more open and international.”
WHERE EVERY STEP OF PRODUCT DEVELOPMENT COMES TO LIFE
Deeply rooted in the heart of the Food Valley where Barilla was born, BITE operates with a global vision: this is where products for all the Group’s brands are developed, bringing the taste of Italy to more than 100 countries. The BITE brings together all stages of food innovation under one roof. Within its 4,800 m², the Innovation Center features dedicated areas for Design Thinking where brainstorms turn into product ideas, tasting and sensory research, and experimental kitchens for pasta and bakery. An additional 9,000 m² of pilot plants host advanced research laboratories and experimental production lines where Barilla’s professionals develop, test and refine new products and processes, together with designing innovative packaging solutions and applying advanced tools to ensure outstanding food quality and safety.
Here, the journey from concept to market takes shape, a process that typically spans around 2 years (and up to 10 for the more complex projects) from researching in the selection of crop varieties and selecting ingredients to recipe development and sensory testing with both expert panels and consumers.
"Innovatingmeans placing people’s desires at the center,” explains Michele Amigoni, Head of RDQ at Barilla Group. “Understanding in depth how their needs related to food and nutrition will evolve, and from there turning ideas into reality that are new, good, and sustainable. The BITE will be a center open to the world, where it will be possible to see, touch, and understand how Barilla envisions the future of food. "
At the BITE, technologies such as the electronic nose and AI-driven smart sensors optimize processes, from mapping aromatic profiles to enhancing pasta drying. 3D printing and holographic design systems enable rapid prototyping and faster development cycles, while the rugosimeter (roughness meter) precisely measures pasta texture at the micron scale, providing valuable data to refine both product quality and the sensory experience. These tools accelerate experimentation and ensure consistency, helping deliver the same Barilla quality to consumers around the world.
COLLABORATING GLOBALLY TO DRIVE INNOVATION
The BITE is the core of an international open innovation network of 84 partnerships with universities, research institutions, and organizations worldwide, from the Ludwig-Maximilians-Universität München in Germany to Purdue University in the US and Wageningen University in the Netherlands, as well as with selected agrifood and tech startups.Since 2019, Barilla’s Good Food Makers accelerator has generated over 1,200 startup applications from 41 countries and launched 28 collaborations, ranging from sustainable indoor agriculture to AI-driven logistics and ingredient traceability.
INCLUSIVE AND SUSTAINABLE SPACES
Designed with sustainability and inclusion at its core, the BITE runs on renewable electric energy and is surrounded by research areas dedicated to the development of regenerative agriculture practices. Through a partnership with Dynamo Academy an Italian social enterprise promoting inclusive design, the building features fully accessible environments, tactile maps and flexible spaces, ensuring a welcoming experience for all.
BARILLA INNOVATION & TECHNOLOGY EXPERIENCE - NUMBERS
- Investment: over €20 million + €2 million per year for plant upgrades
- Surface area: 13,800 square meters in total (4,800 square meters Innovation Center + 9,000 square meters pilot plants)
- Employment: 200 professionals + 30 young talents per year
- Network: 84 active collaborations with universities and research centers
- Tasting: over 1,000 samples tasted annually by certified experts
- Startup ecosystem: 28 active collaborations, 1,200 applications from 41 countries
View source version on businesswire.com: https://www.businesswire.com/news/home/20251118376430/en/


Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
Pivotal Trial Data for EP0031 (A400), a Next-Generation Selective RET Inhibitor (SRI), in RET Positive Advanced NSCLC, to be Presented at ASCO 202622.5.2026 11:18:00 CEST | Press release
Ellipses Pharma (“Ellipses”), a global oncology drug development company with a pipeline of innovative programmes, announced today that its partner, Kelun-Biotech, is presenting pivotal trial data for EP0031/A400, for the potential treatment of RET-fusion positive Non-Small Cell Lung Cancer (NSCLC), at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting Chicago, May 29 to June 2. Efficacy and safety of lunbotinib (A400/EP0031), a next-generation selective RET inhibitor (SRI), from a pivotal phase Ⅱ study in patients with advanced RET-fusion positive non-small cell lung cancer (NSCLC), will be presented as an oral presentation scheduled on May 29, 2026, 14:36-14:48 local time (Abstract #8505: Lung Cancer – Non-Small Cell Metastatic). The oral presentation of these data at the prestigious ASCO annual meeting, represents another major milestone in the global development of EP0031/A400 as a next generation SRI. The data were generated in Kelun-Biotech’s Phase 2 study (NCT0
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom